Research At Johns Hopkins University

Research into Gallbladder and Bile Duct Cancer

Clinical Research

The Johns Hopkins Hospital has been a leader in advancing the current knowledge of the optimal treatments for bile duct cancers. Meticulous studies at Hopkins have allowed the development of specific criteria to determine whether a complete resection should be attempted. Currently, tumors that involve both lobes of the liver, that involve either of the main blood vessels in this area (the portal vein or the common hepatic artery), or that have spread (metastasized) are considered unresectable-such patients receive palliative surgical therapy that has proven to be safe and effective. This includes a nerve (celiac axis) block to relieve pain and bypass procedures (gastrojejunostomy, hepaticojejunostomy) to prevent obstruction of the gastrointestinal tract.

The resectablity rate is highest for tumors of the distal common bile duct (91%) versus those of intrahepatic and perihilar locations (approximately 50% each). The distal common bile duct tumors are treated by the Whipple resection. Such tumors are often difficult to distinguish preoperatively from other tumors that are centered in this area, such as pancreatic adenocarcinomas, duodenal adenocarcinomas that have extended into this area, and true carcinomas of the ampulla of Vater. However, all of these tumors are optimally treated by Whipple resection, after which pathologic analysis of the resection specimen can determine the site of origin and the extent of the tumor. The 10 year survival rates are highest for those arising in the duodenum (59%), followed by those of the ampulla (25%), distal common bile duct (21%), and pancreas (5%). Factors that predict outcome in these patients are the microscopic status of the resection margins (that is, did the cancer extend to the edge of the tissue where the surgeon cut) and lymph node metastases, as well as the degree of differentiation of the tumor. Tumors that microscopically extend to the edges of the resection (positive margin) or those that have spread to regional lymph nodes fare worse. Tumors that closely resemble microscopically the normal glandular epithelium (well-differentiated) fare better than those that do not (poorly differentiated).

Not long ago, the Whipple resection was associated with a high (>10%) operative death rate, and there was considerable debate if the procedure's risks justified the small potential benefits that resection might confer upon patients with very aggressive tumors. Currently the operative mortality of this procedure is a remarkably low 1.4% at Johns Hopkins, which is significantly lower than the rate at other institutions at which this operation is less frequently performed. The operation has been shown to be safe and effective in patients ranging in age up to their 80's, in whom the morbidity and mortality rates approach those of younger patients. Current studies include a prospective randomized trial assessing the effects of additional extended retroperitoneal lymphadenectomy (radical Whipple resection) on the morbidity/mortality of the operation, and the survival of these patients.

Other studies have examined the clinical utility of biochemical tumor markers in following patients at risk for bile duct cancer. A study of patients with primary sclerosing cholangitis found that elevated serum CA19-9 levels (CA19-9 is a blood marker) accurately predicted the presence of cholangiocarcinoma. All patients who proved to have cholangiocarcinoma had elevated serum CA19-9, while no patient without cholangiocarcinoma had an elevated serum CA19-9. Another study found that the levels of carcinoembryonic antigen (CEA) excreted in the bile was elevated in patients with cholangiocarcinoma and in those with intrahepatic gallstones, compared to those with benign bile duct strictures. Those patients with primary sclerosing cholangitis or choledochal cysts had intermediate levels of biliary CEA.

Bile duct cancers have been traditionally considered among the most resistant of all cancers to chemotherapy. Oncologists throughout the world are searching for new agents which will prove more effective. One recent study found that therapy with 5-Fluorouracil combined with subcutaneous injection of interferon 2-alpha produced some effect, though the results are preliminary. Other methods of delivering as much therapy as possible to the tumor while minimizing systemic toxicity, such as intra-arterial pumps, are being explored.

Experimental Research
Most Recent Publications